Ovarian Cancer diagnostics company, Cleo Diagnostics (ASX:COV), has received formal approval from the US National Cancer Institute to access blood samples held within the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial biobank. …
CLEO strengthens FDA submission following Access to globally recognised Biobank
June 25, 2025 Australian Biotech
Latest Video
New Stories
-
New Zealand to streamline access to ADHD treatments
June 26, 2025 - - Latest News -
CLEO strengthens FDA submission following Access to globally recognised Biobank
June 25, 2025 - - Australian Biotech -
Leukaemia Foundation calls for urgent action to address diagnosis and treatment gaps
June 25, 2025 - - Latest News -
QBiotics' candidate produces strong efficacy result in soft tissue sarcoma trial
June 25, 2025 - - Latest News -
Noxopharm says clinical trial recruitment progressing rapidly
June 25, 2025 - - Australian Biotech -
AusBiotech leads global engagement to strengthen Australia's life sciences sector
June 25, 2025 - - Australian Biotech -
NT doctors want action as whooping cough cases soar
June 25, 2025 - - Latest News